# References

SM Vindigni, TL Zisman et al. influence beyond delivery mode, breast-feeding, and antibiotics. J Pediatr Gastroenterol Nutr 51: 77–84.

Feldman, M., Friedman, L. and Brandt, L. (2015) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 10th ed. Philadelphia, PA: Saunders.

Fernandes, P., Macsharry, J., Darby, T., Fanning, A., Shanahan, F., Houston, A. et al. (2015) Differential expression of key regulators of toll-like receptors in ulcerative colitis and Crohn’s disease: a role for Tollip and PPARgamma? Clin Exp Immunol 183: 358–368.

Frank, D., St Amand, A., Feldman, R., Boedeker, E., Harpaz, N. and Pace, N. (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 104: 13780–13785.

Freedberg, D., Toussaint, N., Chen, S., Ratner, A., Whittier, S., Wang, T. et al. (2015) Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149: 883–885 e889.

Fujimoto, T., Imaeda, H., Takahashi, K., Kasumi, E., Bamba, S., Fujiyama, Y. et al. (2013) Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn’s disease. J Gastroenterol Hepatol 28: 613–619.

Gearry, R., Irving, P., Barrett, J., Nathan, D., Shepherd, S. and Gibson, P. (2009) Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease – a pilot study. J Crohns Colitis 3: 8–14.

Gerasimidis, K., Bertz, M., Hanske, L., Junick, J., Biskou, O., Aguilera, M. et al. (2014) Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn’s disease during enteral nutrition. Inflamm Bowel Dis 20: 861–871.

Geremia, A., Biancheri, P., Allan, P., Corazza, G. and Di Sabatino, A. (2014) Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13: 3–10.

Gevers, D., Kugathasan, S., Denson, L., Vazquez-Baeza, Y., Van Treuren, W., Ren, B. et al. (2014) The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15: 382–392.

Gilardi, D., Fiorino, G., Genua, M., Allocca, M. and Danese, S. (2014) Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol 8: 835–846.

Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G. et al. (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305–309.

Gorard, D., Hunt, J., Payne-James, J., Palmer, K., Rees, R., Clark, M. et al. (1993) Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut 34: 1198–1202.

Gough, E., Shaikh, H. and Manges, A. (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53: 994–1002.

Guaraldi, F. and Salvatori, G. (2012) Effect of breast and formula feeding on gut microbiota shaping in newborns. Front Cell Infect Microbiol 2: 94.

Guinane, C., Tadrous, A., Fouhy, F., Ryan, C., Dempsey, E., Murphy, B. et al. (2013) Microbial composition of human appendices from patients following appendectomy. MBio 4: e00366–12.

Guslandi, M. (2011) Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 17: 4643–4646.

Hajishengallis, G., Darveau, R. and Curtis, M. (2012) The Keystone-Pathogen hypothesis. Nat Rev Microbiol 10: 717–725.

Halfvarson, J. (2011) Genetics in twins with Crohn’s disease: less pronounced than previously believed? Inflamm Bowel Dis 17: 6–12.

Halme, L., Paavola-Sakki, P., Turunen, U., Lappalainen, M., Farkkila, M. and Kontula, K. (2006) Family and twin studies in inflammatory bowel disease. World J Gastroenterol 12: 3668–3672.

Hamady, M. and Knight, R. (2009) Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res 19: 1141–1152.

Hansen, J. and Sartor, R. (2015) Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Options Gastroenterol 13: 105–120.

Hedin, C., McCarthy, N., Louis, P., Farquharson, F., McCartney, S., Taylor, K. et al. (2014) Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn’s disease and their unaffected siblings. Gut 63: 1578–1586.

Henker, J., Müller, S., Laass, M., Schreiner, A. and Schulze, J. (2008) Probiotic Escherichia coli Nissle 1917 (ECN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol 46: 874–875.

Heyland, D., Muscedere, J., Wischmeyer, P., Cook, D., Jones, G., Albert, M. et al. (2013) A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med 368: 1489–1497.

http://tag.sagepub.com